Keywords
Neglected Tropical Diseases, Capacity Building, Laboratory Networks, Quality Assurance, Americas, Eastern Mediterranean, Europe, South-East Asia, Western Pacific
This article is included in the Neglected Tropical Diseases collection.
Neglected Tropical Diseases, Capacity Building, Laboratory Networks, Quality Assurance, Americas, Eastern Mediterranean, Europe, South-East Asia, Western Pacific
- In the introduction, methods, results and discussion sections in the revised text we have clarified that the accreditation refers to NTD tests.
- We have stated in the introduction it is a requirement rather than a function of NTD reference laboratories to maintain their own accreditation.
- We have flagged that the total number of staff in the laboratory were not necessarily working full-time on NTD tests.
- We have changed the number of NTDs from "20" to "17".
- We have expanded our recommendations to include that a wide-ranging stakeholder consultation process should be supplemented by in-depth studies including interviews with laboratory staff and users, and decision-makers, to understand the requirements and context in which such laboratories need to operate.
To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.
Laboratories are recognised as one of the weakest elements of health systems due to chronic under-investment. Lack of investment results in poor infrastructure, inadequate numbers and skills of technical staff, insufficient and uncoordinated technical assistance, and lack of diagnostic tools appropriate for low-resource settings1,2. Yet laboratory services are integral to interventions for the surveillance, control and elimination of neglected tropical diseases (NTDs). Laboratories provide clinical and monitoring data about disease prevalence and trends, and are essential for flagging up early signs of drug resistance1,3–6. Appropriate management of clinical cases of NTDs depends on laboratories providing accurate diagnoses for identifying cases5,6. Preventive chemotherapy interventions through mass drug administration (MDA) rely on laboratory data to make decisions regarding intervention effectiveness and for reliably documenting progress towards zero transmission5.
Accelerated scale-up of existing interventions is critical to reach the 2020 NTD Roadmap targets on the control and elimination of NTDs, however, lacking laboratory capacity is a critical bottleneck preventing the international NTD community from meeting targets. There needs to be enhanced laboratory ability in areas with significant NTD prevalence to provide technical and scientific support for the diagnosis, surveillance, monitoring and evaluation of national NTD programmes7. The World Health Organisation’s (WHO) Strategic and Technical Advisory Group (STAG) for Neglected Tropical Diseases have therefore prioritised strengthening the capacity of NTD laboratories and establishing a formal NTD laboratory network which can provide a quality assurance and referral function8.
Globally, few laboratories specialise in NTDs. Laboratory support for NTD programmes is generally provided by parasitology laboratories within national health care systems or research institutions9. Most of these laboratories focus on malaria, and to a lesser extent on soil transmitted helminths (STH), with very little laboratory expertise in other NTDs10. No central register of specialist NTD laboratories exists. NTD laboratory expertise is fragmented and un-coordinated, with no formal referral system or network to provide high level support from internationally-accredited reference laboratories for quality assurance of NTD testing. Consequentially, much laboratory data available on NTDs, that has been used to make important strategic decisions about programme implementation and transmission rates, may have been generated by laboratories working in isolation that are not enrolled in any external quality assurance scheme. The global laboratory infrastructure for NTD control programmes lags behind many other global health programmes, such as those for tuberculosis, malaria, poliomyelitis, measles and hepatitis, which successfully established a globally connected network of laboratories and systems for externally validating disease-specific laboratory data as recommended by the World Health Assembly11,12.
To identify and harness existing capacity and to improve efficiency, laboratories that support national NTD programmes need to be mapped and organised into a functional international network. At the top tier, there should be internationally accredited and interlinked national reference laboratories. Each of which should head a pyramidal referral structure comprising laboratories at, for example, provincial level who support more peripheral district and primary care sites involved in front-line diagnosis and surveillance. A requirement of NTD reference laboratories is to maintain their own accreditation and service quality, and to facilitate provision of quality services by lower level laboratories through, for example, offering training on good laboratory practice and quality management systems, external quality assessment and referral testing, and monitoring performance standards through the organisation of regular proficiency testing1.
Information about the location and expertise of laboratories with specialist NTD expertise across WHO regions is scarce and difficult to access. It is not generally known whether these laboratories meet international accreditation standards for their NTD tests or have the capacity, expertise, and networks that would enable them to operate as national or regional reference centres. Creating a database of laboratories that includes a description of what support they can provide for NTD programmes is an essential first step in the process of establishing an international and regional NTD laboratory network.
This study aimed to identify laboratories that provide NTD services and could be regarded as national or regional reference laboratories within WHO regions, and to document their capacity to support NTD programmes. It covered five of WHO’s six regions since the WHO Africa region office conducted its own complementary study and the results could not be collated due to differing study methods. Our study mapped the geographical distribution and networks of these laboratories, and collated information about the skills and services they provided to support NTD programmes. Scoping the current situation provides a platform on which to design strategies to build an international network of accredited NTD reference laboratories. Such a network is essential to overcome the laboratory bottleneck which is a key barrier in accelerating intervention scale-up to meet 2020 NTD Roadmap goals7.
There is no existing global register of specialist NTD laboratories. This scoping study developed an unbiased and comprehensive way of identifying potential NTD reference laboratories in the five WHO regions – Americas, Eastern Mediterranean, Europe, South-East Asia and Western Pacific. As there was no pre-existing definition of an ‘NTD reference laboratory’, we extracted information from published literature13–17 about the laboratory characteristics needed to fulfil diagnostic, research, supervision, training, quality, and networking requirements of a national or regional reference laboratory for NTDs, and verified them with NTD control programme specialists. These characteristics were:
• able to conduct verifiable quality diagnosis in one or more NTDs
• able to support research into NTDs prevalent in their region
• able to train and mentor staff in national or tertiary level laboratories within the region
• actively networked with other national and international NTD laboratories and research institutions
• evidence of accreditation of NTD tests to international standards (e.g., ISO 15189, Good Clinical Laboratory Practice (GCLP))
Detailed information from the literature about each of these characteristics was used to design an electronic survey administered through Bristol On-line Survey (now Online surveys) to laboratories in the five WHO regions with potential to be national or regional NTD reference laboratories. Topics covered were: location and geographical coverage, NTD tests available, accreditation status, staffing, ability to provide training and technical support, and any capacity gaps the laboratory perceived they had in relation to NTDs.
To identify as many potential regional reference laboratories to include in the survey, and to avoid bias, two wide-ranging search strategies were used. Firstly, key informants were identified from international NTD programmes and research institutions and through WHO regional offices. These included WHO officers in each of the five regions, representatives of multi-lateral agencies supporting laboratory networks and centres, and NTD funders and researchers. Snowballing was used to identify further key informants.
Each key informant was asked to identify which laboratories they were aware of that could be considered an NTD reference laboratory based on our pre-defined list of characteristics. Laboratories did not have to focus exclusively on NTDs, since NTDs may be part of a larger portfolio of work but needed to have a reputation as a referral laboratory (or laboratory unit) for NTDs. 25 key informants provided contact details for 69 laboratories that they considered may be perceived as an NTD reference laboratory.
Secondly, an internet search for potential NTD reference laboratories was conducted. Countries affected by NTDs in each of the five WHO regions were identified from information on NTD strategies and/or activities in documents on WHO regional websites18–23, from country-specific information in the WHO NTD roadmap, and from individuals in the WHO Global Working Group on Capacity Strengthening for national NTD programmes. Overall 60 countries were identified as being affected by and prioritising NTDs in the five WHO regions: The Americas 17 countries, South-East Asia 11 countries, Europe 8 countries, Eastern Mediterranean 14 countries, and Western Pacific 10 countries. Potential NTD reference laboratories were identified by searching websites of national NTD programmes in NTD-affected countries, and the websites of the WHO regional offices, and by following additional links and references provided on these websites. The internet search strategy identified 98 laboratories that may potentially be NTD reference laboratories.
For each identified laboratory, contact details of laboratory heads were obtained from the websites or through key informants. Overall the combined searches yielded 167 contacts in potential reference laboratories. Each contact person was provided with information about the purpose and content of the survey by e-mail and asked to complete the survey. In order to increase response rates, the Modified Dillman approach24 was used which involved fortnightly reminders about the survey for a period of five weeks between October 2013-January 2014 until the survey closed. The survey was also offered in Spanish as appropriate. Following closure of the surveys, 35 telephone calls were made to collect information from non-respondents. These focussed particularly on the European and Americas regions due to low response rates and generated one additional completed survey.
Data from the survey was entered into an excel spreadsheet and anonymised. Data was analysed to provide quantitative, descriptive information, and content analysis was conducted to identify NTD laboratories that met or were close to meeting the characteristics of a reference laboratory.
Nineteen percent (n=32) of the 167 of the laboratory heads contacted responded to the survey. The majority of respondents were from the Eastern Mediterranean region (34%, n=11) (Table 1). No responses were received from the European region. The majority of laboratories (53%, n=17) provided a national level service and 25% (n=8) operated at the international level, predominantly within their own WHO region. The main regional role of surveyed laboratories was the provision of technical support (22%, n=7) and training (22%, n=7) to other laboratories though some were also involved in research, test validation and standard setting (Table 1).
Main characteristics | Laboratories n=32 (%) |
---|---|
Laboratory location (by WHO region) | |
Eastern Mediterranean | 11 (34) |
South-East Asia | 10 (31) |
Western Pacific | 8 (25) |
The Americas | 3 (9) |
Europe | 0 (0) |
Geographical coverage | |
National | 17 (53) |
International | 8 (25) |
Sub-national | 7 (22) |
Regional Role | |
Technical support to other laboratories | 7 (22) |
Providing training for other laboratories | 7 (22) |
Developing, validating and testing NTD methods and protocols | 5 (16) |
Advising on, and meeting, NTD research needs | 5 (16) |
Taking part in standardization on accreditation and certification | 2 (6) |
Other | 6 (19) |
Total number of staff in the laboratory* | |
1–10 | 15 (47) |
11–30 | 9 (29) |
31–50 | 3 (9) |
More than 50 | 5 (16) |
Self-identified capacity gaps | |
Lack of external Quality Assurance | 9 (28) |
Insufficient capacity to provide technical support | 4 (13) |
Insufficient expertise to conduct quality control of laboratory activities linked to NTDs | 3 (9) |
Insufficient capacity to conduct NTD diagnostics | 3 (9) |
Insufficient capacity to conduct NTD research | 3 (9) |
Insufficient capacity to support staff training | 2 (6) |
Inability to promote strategic plan | 1 (3) |
Insufficient funds | 1 (3) |
Insufficient human resource | 1 (3) |
None | 5 (16) |
Laboratories tended to be small with almost half (47 %, n=15) employing 1–10 staff and three-quarters (76%) employing 30 or less. The South-East Asia region had the highest number of staff per laboratory. The Eastern Mediterranean region had the least staff and commonly lacked quality officers, management and administrative staff. Ninety one percent (n=29) of laboratories indicated that their staff had the necessary technical skills to function as an NTD reference laboratory and only one laboratory strongly believed it lacked this technical capacity. Two thirds (69%, n=22) of the laboratories were based in academic institutions and felt they were strong in supporting NTD research. The majority of laboratories (78 %, n=25) identified at least one gap in their capacity, most commonly external quality assurance, which was reported as lacking by 9 (28%) laboratories. The type of capacity gaps was similar across all five regions.
The 32 laboratories covered 17 different NTDs across five WHO regions with 23 laboratories (72%) covering two or more NTDs. Most laboratories within the Eastern Mediterranean region (73%, n=8) specialised in leishmaniasis. Within the Western Pacific region, laboratories tended to focus on STH (50%, n=4) and schistosomiasis (50%, n=4). Laboratories in South-East Asia focused on STH (60%, n=6) and lymphatic filariasis (60%, n=6). Chagas disease, taeniasis, cysticercosis, echinococcosis, onchocerciasis and dengue were the only NTDs covered in the Americas region.
There was variation in adherence to laboratory quality standards. Only four (13%) stated adherence to international standards such as Good Laboratory Practice, ISO 15189 and ISO 9000. 47 percent (15) of laboratories adhered to national quality standards and 40% (13) did not adhere to any. Although 47% (19) of laboratories reported a quality officer, only five (16%) participated in an external quality assurance (EQA) programme for NTD tests. Four of these were in the Eastern Mediterranean region. All five stated that less than 5% of their results within the last 3 years had been unsatisfactory. In the Western Pacific, South-East Asia and Americas regions, at least 90% (12) of laboratories did not participate in an external quality assurance scheme. Fourteen (44%) laboratories had regular interactions with international NTD networks including Drugs for Neglected Diseases Initiative, Tropical Disease Research and regional NTD elimination programmes. International conferences, regional meetings, and NTD workshops, were the predominant modes of networking reported. Despite the majority (91%) of laboratories believing they have the capacity to carry out the role of a reference laboratory, only 14% (n=3) met all the pre-determined characteristics.
This study marks an important step in a process towards creating the need and awareness for an international network of NTD expert laboratories. We used a systematic and wide-ranging approach to identify 32 laboratories distributed across four of five WHO regions which have potential to be regional or national reference laboratories for NTDs. Between them, these laboratories reported that they have the technical skills to provide expertise in 17 different NTDs with each laboratory focussing on NTDs that are prevalent in their region. These laboratories could form the top tier of an interlinked network of laboratories capable of providing quality information for NTD programmes and able to act as NTD research and training centres. Half the laboratories operated at national level and a quarter at regional level and this two-level geographical focus forms a sound basis for creating national and international NTD laboratory networks.
Although over 90% of the laboratories surveyed in this study believed they could act as a reference laboratory, only 3 had all the characteristics required to fulfil this role. Almost all laboratories fell short in the area of standards and quality assurance of laboratory processes. A consistent finding was that 87% of laboratories did not adhere to international quality standards and 40% did not adhere to national quality standards. Further evidence of the paucity of quality systems is that only five of the 32 laboratories participated in an EQA programme for NTD tests; four of these were in the Eastern Mediterranean region. This means there is no independent verification that laboratory results meet international standards. Such verification is imperative in order to generate reliable results and lack of verification undermines confidence in data concerning NTD prevalence, trends and reduced drug efficacy25. Unless NTD data originates from quality assured, accredited laboratories, reports about progress towards global NTD targets will lack credibility.
It is not clear why laboratories felt that they were able to act as reference laboratories even though many did not adhere to national or international quality standards and most were not enrolled in external quality schemes. This finding suggests that the importance of being able to demonstrate that test results are reliable may be under-recognised even among laboratory professionals and that this validation is not demanded by NTD programme managers and other decision makers.
Overall, we contacted 167 laboratories and received information from 32, a third of which were located within the Eastern Mediterranean region; none were in the European region. We used a broad search strategy, so a high response rate was not anticipated since it was likely that many laboratories contacted were not involved in reference-level NTD work. However, it is possible that our search missed some relevant laboratories or that we did not identify some laboratories because contact details were incorrect, or language barriers prevented some managers from responding. The methods used to identify laboratories may have biased the results towards those that are well-known or well-publicised and self-reporting could have led to over-estimation of the capacity of laboratories. The willingness of these laboratories to act as regional reference laboratories was not assessed as part of this study.
The majority of laboratories covered at least two different NTDs. This diversity raises an important question about whether each laboratory should focus on one NTD or several. This will in part be dictated by existing expertise and by the burden of different NTDs in the vicinity. The most efficient use of resources may be to centralise expertise for several NTDs within one laboratory. This would facilitate throughput of large numbers of samples and centralise the expensive, state-of-the-art diagnostic tools needed to provide high levels of diagnostic specificity and sensitivity26–28. Amalgamation of laboratory services for several NTDs is complex and would need to be carefully managed to maintain rigorous systems and quality standards across a large range of services and to get buy-in from national programme managers and other laboratories25.
Most of the laboratories specialising in NTDs are based in research institutions. This is an important factor to consider when planning an international NTD laboratory network since the primary goal of these laboratories is to generate research. This goal may not always be aligned with the priorities of national NTD programmes to provide routine service delivery and training. Research laboratories are characterised by short-term projects with high staff turnover and are strongly influenced by the topical interests of donors. The difference in priorities faced by research laboratories and NTD programmes means that potential tensions need to be anticipated and managed if a research laboratory is the primary provider of national or regional NTD laboratory expertise.
Although only three of the identified laboratories had all the characteristics of a reference laboratory, within each of the four WHO regions surveyed there are at least two laboratories that could be strengthened to reach international accreditation status for NTD tests and fulfil a role as a regional reference centre for NTDs. Responses from these laboratories indicated they have some experience in implementing international laboratory standards, in using advanced diagnostic tools and in providing technical support and training to other laboratories. At least some of the surveyed laboratories have the potential to be in the top global tier as regional reference laboratories once they are able to adhere to international quality standards. If they are integrated into a formal laboratory network, they will be able to, for example, share equipment, develop standardised indicators and regular monitoring protocols for laboratory performance and staff competence29, and provide training, supervision and mentoring for lower tier laboratories.
This study provides preliminary information about the location and expertise of high-level laboratories specialising in NTDs. The data we collected was self-reported by laboratory personnel, so an important next step will be for additional information from European and African NTD laboratories to be incorporated, and for selected laboratories to undergo a more in-depth and independent assessment of their capacity. Criteria then need to be agreed and used to strategically select a small number of laboratories in each region which will be supported technically and financially to achieve international accreditation for NTD tests and formal recognition as regional NTD reference laboratories. These laboratories can then form foci around which to construct a global network of NTD laboratories with the longer term aim of encompassing national and sub-national laboratories within the network. A wide-ranging stakeholder consultation process, likely conducted under the stewardship of the NTD STAG which reports directly to the Director General of WHO, will be needed to define the criteria for selecting laboratories and to define the goal and operation of the NTD laboratory network30. This should be supplemented by in-depth studies including interviews with laboratory staff and users, and decision-makers, to understand the requirements and context in which such laboratories need to operate. Only when this laboratory network is operational will it be possible to have effective and rapid regional and global referral and quality assurance systems and to have confidence in the NTD test results that are essential to support NTD programme operations and research needs12,27.
Dataset 1: De-identified survey data 10.5256/f1000research.16196.d21750131
Potential participants were informed about the purpose and content of the survey and could choose whether or not to complete the survey.
The study was commissioned by the World Health Organization WHO Global Working Group on Capacity Strengthening for National Neglected Tropical Diseases (NTD) Programmes [APW200811893] which reports to the NTD Strategic Technical Advisory Group.
Supplementary File 1: World Health Organization (WHO) regions survey. Includes questions and possible responses
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Public health, health policy and systems, global health governance.
Competing Interests: No competing interests were disclosed.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: laboratory system strengthening; laboratory quality management; laboratory policy and planning
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
References
1. Dean L, Njelesani J, Mulamba C, Dacombe R, et al.: Establishing an international laboratory network for neglected tropical diseases: Understanding existing capacity in five WHO regions. F1000Research. 2018; 7. Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Diseases of poverty, capacity building
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 4 (revision) 02 Dec 18 |
read | ||
Version 3 (revision) 17 Nov 18 |
read | ||
Version 2 (revision) 17 Oct 18 |
read | ||
Version 1 14 Sep 18 |
read |
Click here to access the data.
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
1. The fact that data from the European and African regions are lacking ... Continue reading Please find below our updated responses to your comments to accompany version 4 of the article.
1. The fact that data from the European and African regions are lacking is a major weakness of the article. I would suggest that the authors try to include at least the relevant laboratories from the African region.
We agree that the information from the African region is important missing data. At the start of the study we had extensive discussions with the WHO Africa region team inviting them to participate in this global study. However they were committed to conducting their own study using their own methods which meant that even if we were able to access their data, it would not be directly comparable with our own. At the time WHO AFRO indicated that they would publish their own data about NTD laboratories. We are therefore not able to include any information from the Africa region and we have included in the limitations section of the paper.
2. The authors use a list of 25 NTDs. Which NTDs these are is unclear. WHO uses a list of 20 NTDs (https://www.who.int/neglected_diseases/diseases/en/). It would be good to indicate which list of NTDs the authors use.
We have listed 17 (not 25) NTDs which we included in the survey in the supplementary information to the paper (https://f1000researchdata.s3.amazonaws.com/supplementary/16196/aabfd21a-825a-4ff7-a29b-f76a0c6b951b_WHO_Regions_Survey.pdf ). These comprised the WHO-designated NTDs at the time the survey was designed. It was only later, in 2017, that 3 additional diseases were added to the WHO list (chromoblastomycosis and other deep mycoses, scabies and other ectoparasites, and snakebite envenoming)
3. NTDs are a heterogeneous lot: parasites, viruses, bacteria, fungi. How realistic is it to assume that dedicated NTD laboratories exist? In most cases it will be one or more departments or groups within bigger laboratories.
We agree with the reviewer that we would not necessarily expect to identify many laboratories dedicated to NTDs and have stated this in the second paragraph of the introduction (‘Globally, few laboratories specialise in NTDs. Laboratory support for NTD programmes is generally provided by parasitology laboratories within national health care systems or research institutions ‘). As the reviewer correctly anticipated, we did in fact find that NTD laboratory work was often carried out within larger laboratories including within academic institutions, and we had already mentioned this in the text (for example, in the results section of the abstract).
4. With regard to accreditation: the laboratories that indicate that they have international accreditation: is the NTD testing portfolio included in their scope of accreditation? Otherwise it does not count as accredited lab
Yes the accreditation refers to NTD tests and we have clarified this in the introduction, methods, results and discussion sections in the revised text
5. With regard to human resources: are the numbers in the table the total number of staff in the whole lab or the number of staff actually working on NTDs? The latter is the relevant number.
We agree that ideally we would have liked to know how many staff were dedicated to working on NTDs. However the majority of laboratories were part of a larger organisation (see response to comment 3) and it is likely that the staff in the laboratories were working on non-NTD tests for at least part of the time. We did not ask respondents to estimate how much time was spent working specifically on NTD tests as we suspected that this type of retrospective data would not be robust enough to be meaningful. This is something that could be explored in future studies. We have added a footnote to the table to explain that the staff numbers do not necessarily refer to those only working on NTD tests.
6. Do the authors think that by identifying NTD labs through published literature they may have created a bias towards research-oriented laboratories? Many routine laboratory hardly publish their work (if at all).
We do agree with the reviewer that bias could have been introduced if we had limited our search to only laboratories that published in academic literature. However we recognised this risk in the study design and opted not to use academic publications as a means of identifying potential laboratories to include in the study. Instead we used two wide-ranging search strategies involving a) information about NTD laboratories obtained from key informants (identified from, for example, international NTD programmes and WHO regional offices) and b) identification of potential laboratories from an internet search of websites for documents on NTDs that may contain information about laboratories. Details are already provided in the methods section of the paper.
7. Introduction, paragraph 4: “The role of the NTD reference laboratories is to maintain their own accreditation…” That is not a role, but a requirement to fully function as a reference laboratory. Supporting others to implement a QMS is a role.
We are grateful to the reviewer for this clarification and have adjusted the text accordingly.
8. Methodology paragraph 5: “Overall 60 countries were identified as being affected by and prioritizing NTDs…” The WHO website (see reference under point 2) puts this number at 149. Please explain the discrepancy..
As explained in the paper, and under comment 1 above, we were not able to include data from the Africa region so the number of countries was 60 as we excluded those in the Africa region
9. EQA programmes: I am not surprised that not many labs participate in EQA programs as I know from experience that these are often unavailable outside the big diseases. The ISO standard provides a loophole for this in the form of interlaboratory comparisons. Did the authors identify how many labs work with interlaboratory comparisons for their NTD testing?
We did not collect this information
10. How many of the labs have direct reporting for NTDs to the national disease control programs at MoH level?
We did not collect this information but would hope that these additional in-depth details, which will be essential for establishing a functional NTD laboratory network, will be collected in a subsequent study
11. I am afraid that a network of NTD laboratories is necessary, but will be very difficult to attain: most LMIC have a severe lack of lab staff and a severe lack of funding for their health system in general. NTDs will not be among their first 100 priorities. In many cases NTD testing will have to piggyback on other testing and make use of the leftover resources of the “big” diseases. Also, funding for NTD research is limited and haphazard. I think building a sustainable network will be an enormous challenge.
We agree that establishing a sustainable network of NTD laboratories is an enormous challenge but we are encouraged by the fact that WHO was closely engaged in our study and is firmly committed to the global NTD ‘roadmap’ strategy. Since this study was conducted WHO have reaffirmed their commitment to working towards achieving this goal stating that “The next four years will be crucial in achieving the 2020 targets as we continue to work to integrate interventions into the broader health system and development agenda so that no one is left behind.” http://www.who.int/neglected_diseases/news/WHO_Roadmap_five_years_of_collaboration/en/
12. I think that ultimately more qualitative research with multiple stakeholders (semi-structured interviews, focus group discussions) are needed to really understand how to best design and implement a sustainable laboratory network for NTDs.
This study was the first step on the road towards establishing a global NTD laboratory network and we agree that much more information is needed, including through working closely with a range of stakeholders, before this goal can be achieved. We have added an additional sentence in the conclusion to emphasis this point.
1. The fact that data from the European and African regions are lacking is a major weakness of the article. I would suggest that the authors try to include at least the relevant laboratories from the African region.
We agree that the information from the African region is important missing data. At the start of the study we had extensive discussions with the WHO Africa region team inviting them to participate in this global study. However they were committed to conducting their own study using their own methods which meant that even if we were able to access their data, it would not be directly comparable with our own. At the time WHO AFRO indicated that they would publish their own data about NTD laboratories. We are therefore not able to include any information from the Africa region and we have included in the limitations section of the paper.
2. The authors use a list of 25 NTDs. Which NTDs these are is unclear. WHO uses a list of 20 NTDs (https://www.who.int/neglected_diseases/diseases/en/). It would be good to indicate which list of NTDs the authors use.
We have listed 17 (not 25) NTDs which we included in the survey in the supplementary information to the paper (https://f1000researchdata.s3.amazonaws.com/supplementary/16196/aabfd21a-825a-4ff7-a29b-f76a0c6b951b_WHO_Regions_Survey.pdf ). These comprised the WHO-designated NTDs at the time the survey was designed. It was only later, in 2017, that 3 additional diseases were added to the WHO list (chromoblastomycosis and other deep mycoses, scabies and other ectoparasites, and snakebite envenoming)
3. NTDs are a heterogeneous lot: parasites, viruses, bacteria, fungi. How realistic is it to assume that dedicated NTD laboratories exist? In most cases it will be one or more departments or groups within bigger laboratories.
We agree with the reviewer that we would not necessarily expect to identify many laboratories dedicated to NTDs and have stated this in the second paragraph of the introduction (‘Globally, few laboratories specialise in NTDs. Laboratory support for NTD programmes is generally provided by parasitology laboratories within national health care systems or research institutions ‘). As the reviewer correctly anticipated, we did in fact find that NTD laboratory work was often carried out within larger laboratories including within academic institutions, and we had already mentioned this in the text (for example, in the results section of the abstract).
4. With regard to accreditation: the laboratories that indicate that they have international accreditation: is the NTD testing portfolio included in their scope of accreditation? Otherwise it does not count as accredited lab
Yes the accreditation refers to NTD tests and we have clarified this in the introduction, methods, results and discussion sections in the revised text
5. With regard to human resources: are the numbers in the table the total number of staff in the whole lab or the number of staff actually working on NTDs? The latter is the relevant number.
We agree that ideally we would have liked to know how many staff were dedicated to working on NTDs. However the majority of laboratories were part of a larger organisation (see response to comment 3) and it is likely that the staff in the laboratories were working on non-NTD tests for at least part of the time. We did not ask respondents to estimate how much time was spent working specifically on NTD tests as we suspected that this type of retrospective data would not be robust enough to be meaningful. This is something that could be explored in future studies. We have added a footnote to the table to explain that the staff numbers do not necessarily refer to those only working on NTD tests.
6. Do the authors think that by identifying NTD labs through published literature they may have created a bias towards research-oriented laboratories? Many routine laboratory hardly publish their work (if at all).
We do agree with the reviewer that bias could have been introduced if we had limited our search to only laboratories that published in academic literature. However we recognised this risk in the study design and opted not to use academic publications as a means of identifying potential laboratories to include in the study. Instead we used two wide-ranging search strategies involving a) information about NTD laboratories obtained from key informants (identified from, for example, international NTD programmes and WHO regional offices) and b) identification of potential laboratories from an internet search of websites for documents on NTDs that may contain information about laboratories. Details are already provided in the methods section of the paper.
7. Introduction, paragraph 4: “The role of the NTD reference laboratories is to maintain their own accreditation…” That is not a role, but a requirement to fully function as a reference laboratory. Supporting others to implement a QMS is a role.
We are grateful to the reviewer for this clarification and have adjusted the text accordingly.
8. Methodology paragraph 5: “Overall 60 countries were identified as being affected by and prioritizing NTDs…” The WHO website (see reference under point 2) puts this number at 149. Please explain the discrepancy..
As explained in the paper, and under comment 1 above, we were not able to include data from the Africa region so the number of countries was 60 as we excluded those in the Africa region
9. EQA programmes: I am not surprised that not many labs participate in EQA programs as I know from experience that these are often unavailable outside the big diseases. The ISO standard provides a loophole for this in the form of interlaboratory comparisons. Did the authors identify how many labs work with interlaboratory comparisons for their NTD testing?
We did not collect this information
10. How many of the labs have direct reporting for NTDs to the national disease control programs at MoH level?
We did not collect this information but would hope that these additional in-depth details, which will be essential for establishing a functional NTD laboratory network, will be collected in a subsequent study
11. I am afraid that a network of NTD laboratories is necessary, but will be very difficult to attain: most LMIC have a severe lack of lab staff and a severe lack of funding for their health system in general. NTDs will not be among their first 100 priorities. In many cases NTD testing will have to piggyback on other testing and make use of the leftover resources of the “big” diseases. Also, funding for NTD research is limited and haphazard. I think building a sustainable network will be an enormous challenge.
We agree that establishing a sustainable network of NTD laboratories is an enormous challenge but we are encouraged by the fact that WHO was closely engaged in our study and is firmly committed to the global NTD ‘roadmap’ strategy. Since this study was conducted WHO have reaffirmed their commitment to working towards achieving this goal stating that “The next four years will be crucial in achieving the 2020 targets as we continue to work to integrate interventions into the broader health system and development agenda so that no one is left behind.” http://www.who.int/neglected_diseases/news/WHO_Roadmap_five_years_of_collaboration/en/
12. I think that ultimately more qualitative research with multiple stakeholders (semi-structured interviews, focus group discussions) are needed to really understand how to best design and implement a sustainable laboratory network for NTDs.
This study was the first step on the road towards establishing a global NTD laboratory network and we agree that much more information is needed, including through working closely with a range of stakeholders, before this goal can be achieved. We have added an additional sentence in the conclusion to emphasis this point.